



IUGA 
international urogynecological association

42nd Annual Meeting

June 20 - 24, 2017

Canada

LATE-BREAKING ABSTRACT SUBMISSION GUIDELINES

Submission site opens closes May 1, 2017 at 11:59 pm PST.

Late-breaking abstract submissions are intended to allow for the timely presentation of high impact trials to the 42nd Annual Meeting in Vancouver. It is expected that these abstract submissions are from studies for which *no preliminary data was available at the time of the abstract submission deadline (February 8, 2017).*

This is not a mechanism to update previously submitted preliminary data or to provide an opportunity for previously rejected abstracts to be revised and resubmitted for consideration. Previously rejected abstracts will not be accepted.

Preparation of Abstracts: Will be submitted through the OASIS system; please use the following link: <http://www.call4abstracts.com/iuga/>

Priority will be given (in the following order) to:

- Results of phase III clinical trials
- Results of phase II clinical trials
- Extraordinary findings from a basic science investigation
- Interim analyses of phase III trials that describe important secondary end points
- Prospective multi-institution clinical trials

The authors must fully describe all funding sources for their investigation.

The abstracts will be presented at the podium but will not be published in the abstract book as this submission deadline is past the publisher's deadline.

1. Size: Character count limit is 4200 (excluding spaces, approximately 700 words).

- Allowance for each table: 250 characters
- Allowance for each graph/figure: 750 characters.

2. Title: PLEASE DO NOT INCLUDE THE ABSTRACT TITLE IN THE ABSTRACT TEXT- IT WILL BE ENTERED SEPARATELY. Text will be formatted in BOLD UPPERCASE CHARACTERS. Further editing will be available through the submission system.

3. Author and Disclosures: PLEASE DO NOT INCLUDE AUTHORS OR INSTITUTIONS IN THE ABSTRACT TEXT- THEY WILL BE ENTERED SEPARATELY. Up to 12 Authors and corresponding

contact details may be entered into the submission system. If the abstract is a result of a Study or Working Group, there will be an option to enter the name of this group in the Author Block.

4. Presenting Author: If the author(s) of the abstract is an employee(s) of or has a financial relationship with the commercial interest which controls the content of the presentation then he/she cannot be the presenting author. However, principal investigators responsible for research and development are permitted to present as long as they resolve their COI and as long as they are not employees of the commercial interest.

5. Abstract Submission Format: Only deidentified abstracts will be reviewed. Abstracts with text identifying investigators or the sponsoring institution will be rejected. Please use the required headings listed below to construct your abstract:

- Introduction: Describe the background supporting the relevance of the research question
- Objective: State the purpose of the study or investigation
- Methods: State details on study subjects, techniques, and/or observational/ analytical methods.
- Results: Include your main findings, noting statistically significant data.
- Conclusions: Summarize principal conclusions, emphasizing new and important aspects.
- References: only include citations, no author names, institutions or article titles limit to 3, will be included in total character count.

6. Conflict of Interest and Disclosure Statement: All authors must disclose conflicts of interest. The electronic submission process will not allow abstracts to be submitted without this information being completed for each author listed on the abstract.